Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Glenmark Pharmaceuticals Ltd
Revenue
Glenmark Pharmaceuticals Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
|
Revenue
₹131.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Revenue
₹312.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Revenue
₹269.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Revenue
₹516B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Revenue
₹113B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Revenue
₹103.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Glenmark Pharmaceuticals Ltd
Glance View
Glenmark Pharmaceuticals Ltd., founded in 1977 by Gracias Saldanha, has crafted its journey from a single-product company to a noteworthy player in the global pharmaceutical landscape. Headquartered in Mumbai, India, its growth has been driven by a formidable strategy of focusing on both generics and novel drug discovery. In the fiercely competitive world of pharmaceuticals, Glenmark carved its niche by building a diverse product portfolio that spans across dermatology, respiratory, and oncology segments, among others. The company’s nuanced understanding of therapeutic areas and its pursuit of complex generics have empowered it to not only tap into established markets but also venture into emerging ones across 80 countries. This international strategy, combined with robust research and development infrastructure, underscores how Glenmark leverages scientific innovation to ensure steady revenue streams. At the heart of Glenmark's operations lies its commitment to research-driven growth. The company allocates significant resources to its R&D initiatives, manifesting in state-of-the-art facilities across India, Switzerland, and the U.S. Through these centers, Glenmark focuses on the development of differentiated generic medicines and the discovery of innovative therapeutic molecules. The synergy between its generic and innovative drug segments enables Glenmark to sustain profitability by capitalizing on patent expiries while simultaneously pioneering novel drug therapies. This dual approach not only helps the company secure a competitive position in the pharmaceutical market but also fuels its earnings through a balanced mix of volume-driven sales and premium pricing of differentiated products.
See Also
What is Glenmark Pharmaceuticals Ltd's Revenue?
Revenue
131.3B
INR
Based on the financial report for Dec 31, 2024, Glenmark Pharmaceuticals Ltd's Revenue amounts to 131.3B INR.
What is Glenmark Pharmaceuticals Ltd's Revenue growth rate?
Revenue CAGR 10Y
7%
Over the last year, the Revenue growth was -35%. The average annual Revenue growth rates for Glenmark Pharmaceuticals Ltd have been 3% over the past three years , 5% over the past five years , and 7% over the past ten years .
You don't have any saved screeners yet